Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3378-3387

  Tang, Tracy ^a   Tang, Jean Y ^b   Li, Dongwei ^a   Reich, Mike ^a   Callahan, Christopher A ^a   Fu, Ling ^a   Yauch, Robert L ^a   Wang, Frank ^d,g   Kotkow, Karen ^d,f   Chang, Kris S ^c   Shpall, Elana ^c   Wu, Angela ^c   Rubin, Lee L ^d,e   Marsters Jr , James C ^a   Epstein Jr , Ervin H ^c   Caro, Ivor ^a   De Sauvage, Frederic J ^a  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^d Curis   (United States)

^e Harvard University   (United States)

^f HARVARD STEM CELL INSTITUTE   (United States)

^g ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; PLACEBO; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHEMA; GENE EXPRESSION; HAIR FOLLICLE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MORNING DOSAGE; MOUSE; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DIOXOLES; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PIPERAZINES; PLACEBOS; RECEPTORS, G-PROTEIN-COUPLED; SKIN NEOPLASMS; SMALL MOLECULE LIBRARIES; TREATMENT OUTCOME;

EID: 79955990024     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3370     Document Type: Article

References (32)

1. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003;53:1-114. (Pubitemid 137639458)
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
3. Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998;110:885-8. (Pubitemid 28237693)
4. Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14:78-81. (Pubitemid 26301550)
5. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71. (Pubitemid 26200029)
6. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51. (Pubitemid 26192135)
7. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2. (Pubitemid 28079221)
8. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-803. (Pubitemid 28217449)
9. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997;389:876-81.
10. Undén AB, Zaphiropoulos PG, Bruce K, Toftgård R, Ståhle-Bäckdahl M. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma. Cancer Res 1997;57:2336-40. (Pubitemid 27255884)
11. Aszterbaum M, Epstein J, Oro A, Douglas V, LeBoit PE, Scott MP, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat Med 1999;5:1285-91. (Pubitemid 29535606)
12. Grachtchouk M, Mo R, Yu S, Zhang X, Sasaki H, Hui CC, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat Genet 2000;24:216-7. (Pubitemid 30132187)
13. Nilsson M, Undèn AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A 2000;97: 3438-43. (Pubitemid 30183321)
14. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997;276:817-21. (Pubitemid 27199865)
15. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
16. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci U S A 2003;100:4616-21. (Pubitemid 36457779)
17. Metzger D, Li M, Chambon P. Targeted somatic mutagenesis in the mouse epidermis. Methods Mol Biol 2005;289:329-40.
18. Jonkers J, Meuwissen R, Van Der Gulden H, Peterse H, Van Der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25. (Pubitemid 34326692)
19. Goodrich LV, Milenković L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-13. (Pubitemid 27371635)
20. Skelly JP, Shah VP, Maibach HI, Guy R, Wester R, Flynn GL, et al. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 1987;4: 265-7. (Pubitemid 17110406)
21. St-Jacques B, Dassule HR, Karavanova I, Botchkarev VA, Li J, Danielian PS, et al. Sonic hedgehog signaling is essential for hair development. Curr Biol 1998;8:1058-68. (Pubitemid 28451030)
22. Oro AE, Higgins K. Hair cycle regulation of Hedgehog signal reception. Dev Biol 2003;255:238-48. (Pubitemid 36331946)
23. Müller-Röver S, Handjiski B, Van Der Veen C, Eichmüller S, Foitzik K, McKay IA, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 2001;117:3-15. (Pubitemid 32652434)
24. Lee JN, Jee SH, Chan CC, Lo W, Dong CY, Lin SJ. The effects of depilatory agents as penetration enhancers on human stratum corneum structures. J Invest Dermatol 2008;128:2240-7.
25. Sato N, Leopold PL, Crystal RG. Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. J Clin Invest 1999;104:855-64. (Pubitemid 29536335)
26. Schneider MR, Schmidt-Ullrich R, Paus R. The hair follicle as a dynamic miniorgan. Curr Biol 2009;19:R132-42.
27. Romer JT, Kimura H, Magdaleno S, Sasai K, Fuller C, Baines H, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-40.
28. Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. J Invest Dermatol 1995;104:396-400.
29. Wang GY, Wang J, Mancianti ML, Epstein EH Jr. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 2011;19:114-24.
30. Mancuso M, Pazzaglia S, Tanori M, Hahn H, Merola P, Rebessi S, et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res 2004;64:934-41. (Pubitemid 38176895)
31. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010;28:585-93.
32. Tang JY, Aszterbaum M, Athar M, Barsanti F, Cappola C, Estevez N, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res 2010;3:25-34.